EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY

被引：0
|
作者：
Chen, Bowen [1 ]
Zhang, Linzhi [2 ,3 ]
Cheng, Jiamin, Sr. [2 ]
Yan, Tao [2 ]
Lu, Yinying [1 ]
机构：
[1] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1045
引用
收藏
页码：637A / 638A
页数：2
相关论文
共 50 条
  • [21] Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).
    Bai, Xueli
    Chen, Yiwen
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16131 - E16131
  • [22] Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Wu, Jia-Yi
    Yin, Zhen-Yu
    Bai, Yan-Nan
    Chen, Yu-Feng
    Zhou, Song-Qiang
    Wang, Shuang-Jia
    Zhou, Jian-Yin
    Li, Yi-Nan
    Qiu, Fu-Nan
    Li, Bin
    Yan, Mao-Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1233 - 1240
  • [23] Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
    Zhu, Yun
    Sun, Penghui
    Wang, Kunyuan
    Xiao, Shuzhe
    Cheng, Yanling
    Li, Xiangzhao
    Wang, Biao
    Li, Jiancong
    Yu, Wenxuan
    Cheng, Yang
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [24] Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
    Yun Zhu
    Penghui Sun
    Kunyuan Wang
    Shuzhe Xiao
    Yanling Cheng
    Xiangzhao Li
    Biao Wang
    Jiancong Li
    Wenxuan Yu
    Yang Cheng
    Cancer Cell International, 21
  • [25] Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
    Li, Xiaowei
    Fu, Zhigang
    Chen, Xiaoxia
    Cao, Kunkun
    Zhong, Jiaming
    Liu, Li
    Ding, Ning
    Zhang, Xiaoli
    Zhai, Jian
    Qu, Zengqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers
    Rousset, Perrine
    Nardin, Charlee
    Maubec, Eve
    Heidelberger, Valentine
    Picard, Alexandra
    Gerard, Emilie
    Kramkimel, Nora
    Steff, Maud
    Quereux, Gaelle
    Gaudy-Marqueste, Caroline
    Lesage, Candice
    Mignard, Claire
    Jeudy, Geraldine
    Jouary, Thomas
    Saint-Jean, Melanie
    Baroudjian, Barouyr
    Archier, Elodie
    Mortier, Laurent
    Lebbe, Celeste
    Montaudie, Henri
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy
    Lai, Kuan-Chang
    Chen, Yen-Hao
    Hung, Yi-Ping
    Chiang, Nai-Jung
    Chen, Ming-Huang
    Chen, San-Chi
    HEPATOLOGY INTERNATIONAL, 2024, : 1804 - 1814
  • [28] Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
    Zheng, Zhuangzhuang
    Liu, Zijing
    Zhang, Haifeng
    Guo, Xiao
    Jia, Xiaojing
    Wang, Jianfeng
    Meng, Lingbin
    Xin, Ying
    Jiang, Xin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study
    Teran Brage, E.
    Vidal Tocino, R.
    Moreno Gomez, A.
    Figuero Perez, L.
    Lopez Gutierrez, A.
    Lozano Mejorada, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S325 - S325
  • [30] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Yoshino, Koji
    Yoshikawa, Shusuke
    Uchi, Hiroshi
    Goto, Katsunobu
    Nakamura, Yoshiyuki
    Fukushima, Satoshi
    Kiniwa, Yukiko
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Kawai, Toru
    Hatta, Naohito
    Funakoshi, Takeru
    Teramoto, Yukiko
    Otsuka, Atsushi
    Doi, Haruki
    Ogata, Dai
    Matsushita, Shigeto
    Yamazaki, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345